Overview

The INVIGORATE 2 Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis

Status:
Recruiting

Trial end date:
2023-05-30

Target enrollment:

Participant gender:

Summary

The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in subjects with seasonal allergic conjunctivitis using the environmental exposure chamber (EEC).

Phase:

Phase 3

Details

Lead Sponsor:

Aldeyra Therapeutics, Inc.

Treatments:

Ophthalmic Solutions
Pharmaceutical Solutions